Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 14/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 12/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.94 |
| ▸ | PDGFRA | P16234 | 3/20 | 1.00 |
| ▸ | RAD52 | P43351 | 1/20 | 1.00 |
| ▸ | ABL2 | P42684 | 7/20 | 0.94 |
| ▸ | LYN | P07948 | 3/20 | 0.94 |
| ▸ | SRC | P12931 | 2/20 | 0.94 |
| ▸ | SYK | P43405 | 2/20 | 0.94 |
| ▸ | PLK4 | O00444 | 1/20 | 0.94 |
| ▸ | DDX3X | O00571 | 1/20 | 0.94 |
| ▸ | GAK | O14976 | 1/20 | 0.94 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.94 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.94 |
| ▸ | CA12 | O43570 | 1/20 | 0.94 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.94 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.94 |
| ▸ | EGFR | P00533 | 1/20 | 0.94 |
| ▸ | CA1 | P00915 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imatinib SCHEMBL29377238 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1060852 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1673189 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL8217 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL15632914 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL29370699 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1439360 | 0.99 | ABL1 (0.99) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1440465 | 0.99 | ABL1 (0.99) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL5004429 | 0.99 | ABL1 (0.97) | ABL1BCRKITPDGFRARAD52 | |
| SCHEMBL3859559 | 0.97 | ABL1 (0.94) | ABL1BCRKITPDGFRARAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113171350-B | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20220218707-A1 | USE OF COMPOSITION OF IMATINIB OR DERIVATIVE THEREOF IN PREPARATION OF DRUG FOR PREVENTING, TREATING, AND CONTROLLING ADDICTION RELAPSE | WUHAN UNIVERSITY (CN) | 2022-07-14 | — | — | US | disclosed |
| WO-2021063387-A1 | USE OF COMPOSITION OF IMATINIB AND DERIVATIVE THEREOF IN PREPARATION OF DRUG FOR PREVENTING, TREATING AND CONTROLLING ADDICTION RELAPSE | 武汉大学 | 2021-04-08 | — | — | WO | disclosed |
| US-20210062269-A1 | DATABASES, DATA STRUCTURES, DATA PROCESSING SYSTEMS, AND COMPUTER PROGRAMS FOR IDENTIFYING A CANDIDATE TREATMENT | CARIS MPI, INC. | 2021-03-04 | — | — | US | disclosed |
| US-10258623-B2 | Compositions and methods for reduction of amyloid-beta load | MODGENE, LLC (US) | 2019-04-16 | — | — | US | disclosed |
| EP-3261441-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVES | Neonc Technologies Inc. (US) | 2018-01-03 | — | — | EP | disclosed |
| US-20170360787-A1 | COMPOSITIONS AND METHODS FOR REDUCTION OF AMYLOID-BETA LOAD | MODGENE, LLC | 2017-12-21 | — | — | US | disclosed |
| US-9707231-B2 | Compositions and methods for reduction of amyloid-beta load | MODGENE, LLC (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160287587-A1 | MODIFICATION OF AMYLOID-BETA LOAD IN NON-BRAIN TISSUE | MODGENE, LLC | 2016-10-06 | — | — | US | disclosed |
| WO-2016130800-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2016-08-18 | — | — | WO | disclosed |
| EP-2609064-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2013067157-A1 | COMPOSITIONS AND METHODS FOR REDUCTION OF AMYLOID-BETA LOAD | MODGENE, LLC (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2012027693-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2010057020-A2 | MODIFICATION OF AMYLOID-BETA LOAD IN NON-BRAIN TISSUE | MODGENE, LLC (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120787-A1 | MODIFICATION OF AMYLOID-BETA LOAD IN NON-BRAIN TISSUE | MODGENE, LLC (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2146978-A1 | IMATINIB PRODUCTION PROCESS | Chemagis Ltd. (IL) | 2010-01-27 | — | — | EP | disclosed |
| EP-2076266-A2 | METHOD OF TREATING INFLAMMATORY DISEASES USING TYROSKINE KINASE INHIBITORS | The Board of Trustees of the Leland Stanford Junior University (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008135980-A1 | IMATINIB PRODUCTION PROCESS | CHEMAGIS LTD. (IL) | 2008-11-13 | — | — | WO | disclosed |
| WO-2007143146-A2 | METHOD OF TREATING INFLAMMATORY DISEASES USING TYROSKINE KINASE INHIBITORS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20060188878-A1 | Methods to predict ederma as a side effect of drug treatment | DRESSMAN MARLENE M | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360787-A1 | COMPOSITIONS AND METHODS FOR REDUCTION OF AMYLOID-BETA LOAD | BACE1, APP, BACE2 | ABL1 4148/4885BCR 3519/4885KIT 2999/4885 |
| US-10258623-B2 | Compositions and methods for reduction of amyloid-beta load | BACE1, APP, BACE2 | ABL1 4125/4885BCR 3519/4885KIT 3382/4885 |
| US-20100120787-A1 | MODIFICATION OF AMYLOID-BETA LOAD IN NON-BRAIN TISSUE | BACE1, APP, BACE2 | ABL1 4190/4885BCR 3706/4885KIT 4179/4885 |
| US-20160287587-A1 | MODIFICATION OF AMYLOID-BETA LOAD IN NON-BRAIN TISSUE | BACE1, APP, BACE2 | ABL1 4190/4885BCR 3706/4885KIT 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.